Headline: CPT code 95018: Sequential Incremental Drug and Biologic Skin Test for Immediate Allergic Response

Lead: CPT code 95018 identifies a sequential, incremental skin testing procedure used to determine immediate hypersensitivity to drugs and biological products. The test applies minute amounts of test substances in a controlled escalating or de-escalating sequence, with provider interpretation and a formal report.

CPT code 95018 matters nationally because drug and biologic allergy assessment is central to patient safety, medication selection, and avoidance strategies across outpatient and specialty settings. Accurate coding affects clinical documentation, claims adjudication, and tracking of allergy evaluation services.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical intent of the code, typical sites of service, common billing modifiers referenced for this service, and discussion of where this procedure fits in allergy/immunology practice workflows. The publication summarizes reimbursement and coverage considerations at a high level, highlights billing documentation elements tied to interpretation and reporting, and outlines where additional payer-specific policy review is required.

This summary is designed for coding professionals, practice managers, and allergy/immunology clinicians who need a concise national view of CPT code 95018 and its role in immediate hypersensitivity evaluation.